Global WholeHealth Partners Corporation (GWHP) Research

Global WholeHealth Partners Corporation, established in 2013 and based in San Clemente, California, is dedicated to the development and distribution of a diverse array of in-vitro diagnostic test kits across the United States. The company provides swift diagnostic solutions, including rapid assays for CoVid-19, whole blood Ebola, whole blood Zika, and whole blood tuberculosis (TB), among other tests. These diagnostic tools are designed for wide accessibility, catering to both over-the-counter consumer purchases and professional point-of-care settings such as hospitals, physicians' offices, and various medical clinics. Their product line effectively identifies a multitude of diseases, encompassing infections like Ebola, Zika, dengue, malaria, influenza, tuberculosis, coronaviruses, and other conditions transmitted by vectors.

Market snapshot

Symbol
GWHP
Price
$0.00
Day change
-90.00%
Market cap
$1.3K
P/E ratio
-0.00x
52-week range
1.0E-6-2.0E-4
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
  • The Greenrose Holding Company Inc. (GNRS)
  • Micron Solutions, Inc. (MICRD)
  • MEDirect Latino, Inc. (MLTO)
  • Molecular Templates, Inc. (MTEM)
  • Orchid Ventures, Inc. (ORVRF)
  • RxElite, Inc. (RXEI)
  • Signature Eyewear, Inc. (SEYE)

Open Global WholeHealth Partners Corporation (GWHP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.